Effect of Banhasasim-tang on the Hepatic and Splenic Toxicity induced by Doxorubicin

반하사심탕(半夏瀉心湯)이 Doxorubicin에 의해 유발(誘發)된 간장(肝臟) 및 비장(脾臟) 독성(毒性)에 미치는 영향(影響)

  • Hwang, Hui-Jeung (Dept. of Internal Medicine, College of Oriental Medicine, Kyungsan University) ;
  • Shin, Min-Kyu (Dept. of Internal Medicine, College of Oriental Medicine, Kyungsan University) ;
  • Kwak, Min-Ah (Dept. of Internal Medicine, College of Oriental Medicine, Kyungsan University) ;
  • Lee, Yun-Hee (Dept. of Internal Medicine, College of Oriental Medicine, Kyungsan University) ;
  • Kim, Sang-Chan (Dept. of Formulae Pharmacology, College of Oriental Medicine, Kyungsan University) ;
  • Byun, Joon-Seok (Dept. of Internal Medicine, College of Oriental Medicine, Kyungsan University)
  • 황희정 (경산대학교 한의과대학 내과학 교실) ;
  • 신민규 (경산대학교 한의과대학 내과학 교실) ;
  • 곽민아 (경산대학교 한의과대학 내과학 교실) ;
  • 이윤희 (경산대학교 한의과대학 내과학 교실) ;
  • 김상찬 (경산대학교 한의과대학 방제학 교실) ;
  • 변준석 (경산대학교 한의과대학 내과학 교실)
  • Published : 2002.12.30

Abstract

Object The effect of Banhasasim-tang extracts on the hepatic, splenic toxicity and induced by Doxorubicin administration(Three injection protocol) were monitored using male ICR mice. Method The changes of body weigh, organ weights of liver and spleen were observed with blood GOT and GPT level. Results 1. Increase of absolute and relative liver weight observed in Doxorubicin treatment group were dose-dependently inhibited by Banhasasim-tang extracts. In addition, the degrees of liver congestion and necrotic spot were significantly and dose-dependently decreased after Banhasasim-tang extracts dosing groups compared to that of Doxorubicin treatment group. It is also demonstrated that elevated serum GOT and GPT levels in Doxorubicin treatment group were significantly decreased in Banhasasim-tang extracts dosing groups. 2. Decrease of absolute and relative spleen weight observed in Doxorubicin treatment group were dose dependently inhibited by Banhasasim-tang extracts. In addition, the degrees of splenic atrophy were significantly and dose-dependently decreased after Banhasasim-tang extracts dosing groups compared to that of Doxorubicin treatment group.

Keywords

References

  1. Cancer Res. v.61 Attenuation of Doxorubicin chronic toxicity in metallothionein-overerpressing transgenic mouse heart. Sun, X.;Zheu, Z;Kang, Y. J.
  2. Oncol v.19 The anthracyclines: will we ever find a better Doxorubicin Semin Weiss, R.B.
  3. J. Am. Med. Assoc. v.266 Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Steinherz, L.J.;Steinherz, P.G.;Tan, C.T.;Heller, C.;Murphy. M.L.
  4. Hum. Exp.Toxicol. v.11 Preclinical toxicology of a noveklpolymeric antitumour agent. HPMA copolymer-Doxorubicin(PK 1 ). Duncan, R.;Coatsworth, J.K.;Burtles, S.
  5. 동서의학결합치료2 암 문구;정병학;김병주
  6. In Vivo v.7 Preclinical toxicology study of liposome encapsulated Doxorubicin(TLC D-99). comparison wlth Doxorubicin and empty liposome in mice and dogs. Kanter, P. M.;Builard, G. A.;Pilkiewicz, F.G.;Mayer, L. D.;Cuilis, P. R.;Pavelic,Z.P.
  7. Eur. J. Pharmacol v.414 Cardioprotective effects of zofenopril, a newangiotensin-converting enzyme inhibitor, on Doxorubicin-induced cardiotoxicity in the rat. Sacco, C.;Blglonl, M.;Evangellsta, S.;Goso, C.;Manzlni, S.;Maggl, C.A.
  8. Anticancer Drug Des. v.15 Prevention of adriamycin-induced mdrlgene amplification and expression in mouse leukemia cells by simultaneous treatment with the anti-recombinogen bromovinyl-deoxyuridine. Fahrig, R.;Steinkamp-Zucht, A.;Schaefer, A.
  9. 半邊蓮과 항암제의 B16-F0 melanoma cell에 대한 항종양 효과 張熙一
  10. 抗癌生血湯이 Methotrexate로 유발된 부작용과 면역기능 저하에 미치는 영향 李峻溶
  11. 少陰人補中益氣湯과 少陰人補中益氣湯加味方의 항암효과 및 Cyclophosphomide에 의한 부작용에 미치는 영향 郭桂豪
  12. 金궤票略註釋 李克光
  13. 半夏瀉心湯의 效能에 관한 실험적연구 朴治洙
  14. 半夏瀉心湯과 cimetidine의 병용투여가 흰쥐의 위궤양에 미치는 영향 복진우
  15. 半夏瀉心湯 및 半夏瀉心湯加赤石胎가 實驗的 胃潰瘍에 미치는 영향 조남수
  16. 本草學 v.3 全國韓醫科大學 本草學敎室
  17. 방제학 李尙仁;金東傑;金永坂;盧昇鉉;朴宣東;李暎鍾;周榮丞
  18. Toxicol. Sci. v.60 Single-dosed toxicity study of hepatic intra-arterial infusion of Doxorubicin coupled to a novel magnetically targeted drug carrier Goodwin, S. C.;Bittner, C. A.;Peterson, C.L.;Wong G.
  19. Res. Commun. Chem. Pathol. Pharmacol. v.74 The effect of chronic administeration of Doxorubicin on the rat cardiac and hepatic glutathion redox system Powell, S. R.;Chevion, M.
  20. Cancer Res. v.47 Effect of allyl alcohol-induced sublethal hepatic damage upon Doxorubicin metabolism and toxicity in the rabbit Brenner, D. E.;Anthony, L. B.;Halter, S.;Harris, N. L.;Collins, J. C.;Hande, K. R.(etc).
  21. J. A. M. A. v.256 Subclinical hepatic toxicity during combination chemotherapy for breast cancer Larroquette, C.A.;Hortobagyi, G.N.;Buzdar, A.U.;Holmes, F.A.
  22. Arch. Pathol. Lab. Med. v.108 Hepatic injury during Doxorubicin therapy Aviles, A.;Herrera, J.;Ramos. E.;Ambriz,R.;Aguirre, J.;Pizzuto, J.
  23. Acta. Physiol. Hung. v.64 Inhibition of Doxorubicin-induced liver toxicity by a new dihydroquinoline type antioxidant Sreter, I.;Kiss, A.;Comides, A.;Vereckei, A.;Toncsev, H.;Feher, J.
  24. Small animal clinical diagnosis by laboratory methods v.1 Willard, M.D.
  25. Phytomedicine v.7 Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from Uncaria tomentosa Sheng, Y.;Pero, R. W.;Wagner, H.
  26. Toxicol. Pathol. v.22 BR96-Doxorubicin conjugate(BMS-182248) versus Doxorubicin: a comparative toxicity assessment in rats. Comereski, C.R.;Peden. W.M.;Davidson, T.J.;Warner, G.L.;Hirth, R.S.;Frantz, J.D.
  27. J. Pharmacol. Exp. Ther. v.92 Metallothionein act as a cytoprotectant against Doxorubicin toxicity Kimura, T.;Fujita I.;Itoh, N.;Muto, N.;Nakanishi, T.;Takahashi, K.(etc.)
  28. Toxicology v.95 Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage,and enhanced excretion of urinary lipldmetabolites in rats Bagchi. D.;Bgchi, M.;Hassoun,E. A.;Kelly,J.;Stohs,S. J.
  29. Tumori v.86 Modulatory effects of melatonin and vitamine E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice. Wahab, M. H.;Akoul, E. S.;Abdel-Aziz, A.A..